These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 32332858)

  • 21. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma.
    Kiffin R; Johansson J; Olofsson Bagge R; Martner A
    Eur J Surg Oncol; 2021 Sep; 47(9):2460-2464. PubMed ID: 33980416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies.
    Audsley KM; Wagner T; Ta C; Newnes HV; Buzzai AC; Barnes SA; Wylie B; Armitage J; Kaisho T; Bosco A; McDonnell A; Cruickshank M; Fear VS; Foley B; Waithman J
    Front Immunol; 2021; 12():735133. PubMed ID: 34552594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
    Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
    PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.
    Huang Y; Peng M; Yu W; Li H
    Int Immunopharmacol; 2024 Sep; 138():112534. PubMed ID: 38941667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.